Advances in Lymphoma
Transcript: Safety strategies in CAR T-cell
Professor Andrés Ferreri
All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
Well, in particular, in the field of CAR T-cell therapy, there were some studies with very encouraging results that are focused on three different issues. The first one is the improvement of the safety of the CAR T-cells. An example is a trial where the patients were treated with a form of long-lasting interleukin 7, which is able to increase the expansion of the CAR T-cells, but in a way that it would be reduced, associated with a reduced risk of cytokine release syndrome and ICANS .
Another similar strategy is those using the RNA technology to modify the CAR T-cells in a way that produces interleukin 6, and in this way, to reduce the release of the cytokines, and to reduce the effect, the toxic effect , which are one of the major concerns with the use of CAR T-cells.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event